Tropical Medicine
Irritable bowel syndrome (IBS)
Tropical Medicine
Well covered in the main question banks · 44 main-bank entries · 24 linked PDF entries · 0 generated drills
Prerequisites and related lessons
- Constipation
- Diverticular disease
Curriculum reference · Official College Textbook – Digestive Disorders – Part 1, pp. 234–237. Lesson adapted from Internal Medicine and Tropical Medicine.
Topic map
- Mechanismdisorder of gut–brain interaction
- Patternpain related to bowel movements, frequency or form
- Subtypesconstipation, diarrhea, mixed, unclassified
- Treatsubtype, diet and gut–brain contributors
Scroll the diagram to see all labels.
Definition and pathophysiology
Irritable bowel syndrome is a functional disorder [IM Mid Q1], now termed a disorder of gut–brain interaction. Abnormal signaling between bowel and brain, visceral hypersensitivity, motility changes, microbial or postinfectious change and psychological stress can interact. Symptoms are real and need not reflect visible tissue disease. Anxiety, depression, sleep disturbance and extraintestinal symptoms may coexist. IBS can develop after gastroenteritis. It is not a progressive destructive or premalignant condition.
Rome IV requires recurrent abdominal pain on average at least one day per week in the last three months, with at least two of the following: related to defecation, change in stool frequency, change in stool form. Symptoms must have begun at least six months before diagnosis. Pain relieved by defecation [IM Mid Q8/Q12] is common, but “related to” includes worsening. Patients may describe bloating, mucus, urgency or incomplete evacuation. Bristol forms 1–2 are hard and 6–7 loose. On abnormal-stool days, >25% hard and <25% loose suggests IBS-C; reverse suggests IBS-D; both >25% suggests IBS-M; otherwise IBS-U. Functional constipation and functional diarrhea lack the defining recurrent pain pattern.
Assessment and differentials
- Initial assessment
- Positive symptom criteria and screening for alarms
- Confirmation or next test
- Targeted tests for celiac disease, inflammation or other mimics by phenotype
Look for blood, iron deficiency anemia, unexplained weight loss, nocturnal diarrhea, older/new onset or family history of colorectal cancer, celiac disease or IBD [IM Mid Q4–6/Q9 · Book I]. These are reasons to reconsider the diagnosis or use targeted work-up. Longstanding typical symptoms alone are not a reason for colonoscopy. Screen by age and risk. CBC and targeted inflammatory markers can help. In diarrhea-predominant symptoms, consider celiac serology (tTG-IgA with total IgA on gluten) and fecal calprotectin or lactoferrin to assess IBD risk. Select stool testing by exposure. Persistent alarm-pattern diarrhea may require ileocolonoscopy and biopsies for IBD/microscopic colitis or upper endoscopy for celiac evaluation.
An IM Mid case with persistent diarrhea and weight loss on a gluten-free diet keys upper endoscopy with small bowel biopsy [IM Mid Q6]. Diet can normalize serology and histology. Confirm the history and gluten exposure, assess alternatives, and consider HLA or supervised gluten challenge through a specialist when appropriate. Bile acid diarrhea, lactose malabsorption, infection and medication effects can resemble IBS-D. The IM Mid typical 30-year-old with work-related symptoms and no weight loss does not require blanket invasive testing; targeted tests remain appropriate when the phenotype calls for them.
Management
Explain the disorder, agree on symptom goals, promote activity, regular meals and hydration. Soluble fiber such as psyllium can help, while abrupt insoluble fiber loading can worsen bloating. Use a limited dietitian-guided low-FODMAP trial [IM Mid Q7] if appropriate, followed by reintroduction and personalization. FODMAPs are fermentable carbohydrates that can draw water and generate gas.
For IBS-C, osmotic agents can improve stool frequency; pain may need separate treatment. Lubiprostone [IM Mid Q2] increases chloride-mediated secretion and is a course choice. Linaclotide or plecanatide activate guanylate cyclase-C, and choices depend on availability and patient factors. For IBS-D, loperamide can reduce diarrhea without reliably improving global symptoms. Options include rifaximin, selected bile acid treatment when another cause is identified, and selected other agents. The exam keys a 5-HT3 receptor antagonist [IM Mid Q3]; alosetron is restricted to selected severe refractory cases because of serious adverse effects. Low-dose tricyclics, peppermint oil or other symptom-directed approaches may help in appropriate patients. Gut-directed CBT or hypnotherapy addresses gut–brain mechanisms. Reassess diagnosis if alarms develop or the course changes.
Exam traps
Bloody diarrhea is not an expected IBS feature. IBS requires pain rather than bloating alone. A predictable link to defecation supports IBS, even if stool subtype alternates. Ruling out every possible disease is unnecessary with a characteristic pattern and proportionate evaluation.
Diagnostic and management pathways
- Recurrent pain plus altered stool → apply Rome criteria and subtype
- Alarm features or screening need → targeted investigation before labeling IBS
- Typical pattern → symptom-focused treatment and reassessment
- Diet/drug choice → subtype and safety, with gut-directed support when useful
Compare at a glance
| Disorder | Discriminator | Useful next step |
|---|---|---|
| IBS | Pain linked to defecation or altered stool, no alarms | Positive diagnosis and subtype-directed care |
| IBD | Bleeding, nocturnal diarrhea or inflammation | Calprotectin and endoscopy as indicated |
| Celiac disease | Malabsorption, anemia, weight loss or family history | Serology while consuming gluten; selective biopsy |
| Microscopic colitis | Persistent watery diarrhea, often older age | Colonic biopsies even with normal-appearing mucosa |
Supplementary clarification – not directly stated in the uploaded materials. Clinical references · ACG irritable bowel syndrome guideline
Exam words
- Irritable bowel syndrome is a functional disorder [IM Mid Q1]
- Pain relieved by defecation [IM Mid Q8/Q12]
- blood, iron deficiency anemia, unexplained weight loss, nocturnal diarrhea, older/new onset or family history of colorectal cancer, celiac disease or IBD [IM Mid Q4–6/Q9 · Book I]
- upper endoscopy with small bowel biopsy [IM Mid Q6]
- limited dietitian-guided low-FODMAP trial [IM Mid Q7]
- Lubiprostone [IM Mid Q2]
- 5-HT3 receptor antagonist [IM Mid Q3]
Practice questions
Rapid revision sheet
Sixty-second recall. Say the definition, the key clue and the next clinical step out loud before checking the list.
- Irritable bowel syndrome is a functional disorder [IM Mid Q1]
- Pain relieved by defecation [IM Mid Q8/Q12]
- blood, iron deficiency anemia, unexplained weight loss, nocturnal diarrhea, older/new onset or family history of colorectal cancer, celiac disease or IBD [IM Mid Q4–6/Q9 · Book I]
- upper endoscopy with small bowel biopsy [IM Mid Q6]
- limited dietitian-guided low-FODMAP trial [IM Mid Q7]
- Lubiprostone [IM Mid Q2]
Official College Textbook – Digestive Disorders – Part 1, pp. 234–237
Active recall
Which symptom is central to Rome IV IBS and helps separate it from functional constipation?
Recurrent abdominal pain associated with defecation or a change in stool frequency or form. Rome IV requires at least two of these three associations.
Official College Textbook – Digestive Disorders – Part 1, pp. 234–237
Recall the diagnostic and management pathway from memory.
Start with the presenting clue, name the first assessment, then distinguish confirmation, immediate management and follow-up.
- Recurrent pain plus altered stool → apply Rome criteria and subtype
- Alarm features or screening need → targeted investigation before labeling IBS
- Typical pattern → symptom-focused treatment and reassessment
- Diet/drug choice → subtype and safety, with gut-directed support when useful